To include your compound in the COVID-19 Resource Center, submit it here.

Olumiant meets Phase III endpoints for atopic dermatitis

Eli Lilly and Co. (NYSE:LLY) and Incyte Corp. (NASDAQ:INCY) said Olumiant baricitinib met the primary endpoints

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE